Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases
Shots: Beam to receive $50M up front and $25M as near-term milestones & will be eligible to receive other milestones along with royalties on sales, following the exercise of the option. The companies will work on 6 research programs focusing on C3 & other complement targets in the eye, liver, and brain Apellis holds exclusive […]